Atrial selectivity of antiarrhythmic drugs

Antiarrhythmic drugs in the management of atrial fibrillation.

Can polymorphisms predict response to antiarrhythmic drugs in atrial fibrillation?

Ready or not, routine use of genetic information is imminent in everyday cardiology practice. This impending reality stems partly from the declining cost of whole-genome sequencing that is now approaching the $1,000 barrier. Clinicians undoubtedly could use such insight in managing atrial fibrillation (AF), an extremely common and costly condition. However, analyzing and applying the vast amoun...

Antiarrhythmic drugs.

Most patients with cardiac arrhythmias require treatment with antiarrhythmic drugs, although recent advances in surgical and electrical techniques are promising. The ideal antiarrhythmic compound should have: (1) A wide range of therapeutic activity in both atrial and ventricular arrhythmias. (2) Parenteral and oral formulations to permit simple dosage schedules. (3) Pharmacokinetic properties ...

Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation

Background—The mainstay of treatment for atrial fibrillation (AF) remains pharmacological; however, catheter ablation has increasingly been used over the last decade. The relative merits of each strategy have not been extensively studied. Methods and Results—We conducted a randomized multicenter comparison of these 2 treatment strategies in patients with paroxysmal AF resistant to at least 1 an...

Antiarrhythmic Drugs

Cardiac arrhythmias result from alterations in the orderly sequence of depolarization followed by repolarization in the heart. Cardiac arrhythmias may result in alterations in heart rate or rhythm and arise from alterations in impulse generation or conduction. The clinical implications of disordered cardiac activation range from asymptomatic palpitations to lethal arrhythmia. Pharmacological ma...